<DOC>
	<DOC>NCT01177410</DOC>
	<brief_summary>The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.</brief_summary>
	<brief_title>Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Male or nonpregnant, nonlactating female subjects Diagnosed with IBS confirmed by the Rome III criteria Meet the following IBS symptom scores in all categories during the diary eligibility period: An average daily score of greater than or equal to 3 for abdominal pain An average daily score of greater than or equal to 3 for bloating An average daily score of 5 or greater for stool consistency using the Bristol Stool Scale Does not have adequate relief of IBS symptoms (weekly reported) over the past 7 days on the first day of screening and on the day of randomization Present with hard or lumpy stools (Type 1 or Type 2) on the Bristol Stool form Scale during the diary eligibility period history of inflammatory bowel disease has Type 1 or 2 diabetes pregnant or lactating history of HIV or hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>IBS</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>IBS-D</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>Bloating</keyword>
</DOC>